Effect of nicotinamide on C-peptide levels in insulin-dependent diabetes mellitus

Gourni, M; Roupa, Z; Marvaki, C; Ardavanis, A; Sotiropoulou, P; Gourni, P; Bartsokas, C

dc.contributor.author	Gourni, M	en
dc.contributor.author	Roupa, Z	en
dc.contributor.author	Marvaki, C	en
dc.contributor.author	Ardavanis, A	en
dc.contributor.author	Sotiropoulou, P	en
dc.contributor.author	Gourni, P	en
dc.contributor.author	Bartsokas, C	en
dc.date.accessioned	2014-03-01T01:54:26Z
dc.date.available	2014-03-01T01:54:26Z
dc.date.issued	2005	en
dc.identifier.issn	10116583	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/27377
dc.relation.uri	http://www.scopus.com/inward/record.url?eid=2-s2.0-20044370139&partnerID=40&md5=6ad0bd9630258772d37b51ce0c5414e2	en
dc.subject	C-peptide	en
dc.subject	Insulin-dependent diabetes mellitus	en
dc.subject	Nicotinamide	en
dc.subject.other	C peptide	en
dc.subject.other	insulin	en
dc.subject.other	nicotinamide	en
dc.subject.other	placebo	en
dc.subject.other	adolescent	en
dc.subject.other	article	en
dc.subject.other	child	en
dc.subject.other	clinical article	en
dc.subject.other	clinical trial	en
dc.subject.other	controlled clinical trial	en
dc.subject.other	controlled study	en
dc.subject.other	diarrhea	en
dc.subject.other	headache	en
dc.subject.other	hot flush	en
dc.subject.other	human	en
dc.subject.other	insulin dependent diabetes mellitus	en
dc.subject.other	insulin treatment	en
dc.subject.other	nausea	en
dc.subject.other	pilot study	en
dc.subject.other	prospective study	en
dc.subject.other	randomized controlled trial	en
dc.subject.other	statistical significance	en
dc.title	Effect of nicotinamide on C-peptide levels in insulin-dependent diabetes mellitus	en
heal.type	journalArticle	en
heal.publicationDate	2005	en
heal.abstract	The aim of this study is to assess the effect of nicotinamide to c-peptide levels in children during the first six weeks of insulin-dependent diabetes mellitus (IDDM). Thirty-eight children and adolescents, with recent diagnosis (≤ 6 weeks) of IDDM were studied. Patients were randomized in two groups. In Group A patients received insulin and placebo, while in group B insulin and nicotinamide. Serum c-peptide levels were measured at 0, 3, 6, 9 and 12 months. The total dose of insulin administered the day preceding each sampling was recorded. Results: there was a significant difference between the various average values of c-peptide levels during the second trimester with p=0.01 for group A and p=0.02 for group B. No statistically significant difference was found between the two groups. Similar findings were observed for insulin-dose. Toxicity was negligible and similar in both groups. In conclusion, the treatment of newly diagnosed IDDM with NA does not significantly affect c-peptide levels for a period of time exceeding 6 months. However, this small-size pilot study should be confirmed by a large randomized study with different design involving NA treatment before clinical IDDM. © PHARMAKON-Press.	en
heal.journalName	Review of Clinical Pharmacology and Pharmacokinetics, International Edition	en
dc.identifier.volume	19	en
dc.identifier.issue	1	en
dc.identifier.spage	37	en
dc.identifier.epage	42	en